Laura James
Concepts (569)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acetaminophen | 62 | 2025 | 276 | 12.500 |
Why?
| Analgesics, Non-Narcotic | 28 | 2025 | 117 | 5.340 |
Why?
| Liver | 25 | 2025 | 1132 | 3.010 |
Why?
| Drug Overdose | 16 | 2024 | 159 | 3.010 |
Why?
| Liver Failure, Acute | 13 | 2024 | 56 | 2.500 |
Why?
| Hepatocytes | 15 | 2018 | 178 | 2.310 |
Why?
| Liver Regeneration | 9 | 2019 | 47 | 1.930 |
Why?
| Alanine Transaminase | 17 | 2023 | 119 | 1.280 |
Why?
| MicroRNAs | 4 | 2020 | 344 | 1.260 |
Why?
| Adolescent | 47 | 2025 | 6447 | 1.200 |
Why?
| Male | 88 | 2025 | 25923 | 1.200 |
Why?
| Proton Pump Inhibitors | 7 | 2024 | 83 | 1.140 |
Why?
| Acetylcysteine | 13 | 2019 | 101 | 1.140 |
Why?
| Cytochrome P-450 CYP2E1 | 4 | 2020 | 111 | 1.140 |
Why?
| Mitochondria, Liver | 10 | 2015 | 69 | 1.110 |
Why?
| Child | 43 | 2025 | 6907 | 1.050 |
Why?
| Oxidative Stress | 12 | 2023 | 772 | 1.040 |
Why?
| Cytochrome P-450 CYP3A | 3 | 2020 | 77 | 1.030 |
Why?
| Humans | 106 | 2025 | 50578 | 0.980 |
Why?
| Chromatography, High Pressure Liquid | 10 | 2016 | 326 | 0.900 |
Why?
| Child, Preschool | 29 | 2024 | 3942 | 0.890 |
Why?
| Female | 67 | 2025 | 27148 | 0.860 |
Why?
| Cytokines | 8 | 2012 | 606 | 0.860 |
Why?
| Attitude | 2 | 2021 | 69 | 0.850 |
Why?
| Asthma | 4 | 2022 | 284 | 0.850 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2012 | 57 | 0.840 |
Why?
| Animals | 42 | 2025 | 13125 | 0.840 |
Why?
| Proteins | 4 | 2016 | 339 | 0.800 |
Why?
| Rape | 1 | 2022 | 14 | 0.790 |
Why?
| Vitamin D Deficiency | 1 | 2022 | 44 | 0.780 |
Why?
| Crime Victims | 1 | 2022 | 34 | 0.760 |
Why?
| Sex Offenses | 1 | 2022 | 75 | 0.720 |
Why?
| Health Facilities | 1 | 2021 | 40 | 0.710 |
Why?
| Mice | 30 | 2025 | 5687 | 0.710 |
Why?
| Cysteine | 7 | 2024 | 50 | 0.690 |
Why?
| Inflammation | 3 | 2020 | 610 | 0.690 |
Why?
| Naphthalenes | 9 | 2018 | 121 | 0.670 |
Why?
| Cytochrome P-450 CYP1A2 | 4 | 2020 | 38 | 0.670 |
Why?
| Health Services Accessibility | 2 | 2021 | 428 | 0.660 |
Why?
| Indoles | 9 | 2018 | 278 | 0.660 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2011 | 182 | 0.660 |
Why?
| Liver Diseases | 4 | 2023 | 80 | 0.650 |
Why?
| Bronchoconstriction | 1 | 2019 | 6 | 0.640 |
Why?
| Mitochondria | 2 | 2020 | 399 | 0.630 |
Why?
| 2-Pyridinylmethylsulfinylbenzimidazoles | 4 | 2018 | 19 | 0.610 |
Why?
| Aspartate Aminotransferases | 8 | 2015 | 43 | 0.600 |
Why?
| Bronchodilator Agents | 1 | 2019 | 76 | 0.580 |
Why?
| Radius | 1 | 2018 | 27 | 0.580 |
Why?
| Immunoassay | 1 | 2016 | 20 | 0.540 |
Why?
| Aryl Hydrocarbon Hydroxylases | 4 | 2014 | 74 | 0.540 |
Why?
| Mice, Inbred C57BL | 16 | 2025 | 1808 | 0.540 |
Why?
| Serum | 1 | 2016 | 32 | 0.530 |
Why?
| Anti-Bacterial Agents | 6 | 2023 | 745 | 0.530 |
Why?
| Imines | 4 | 2025 | 14 | 0.530 |
Why?
| Gastroesophageal Reflux | 4 | 2018 | 50 | 0.520 |
Why?
| Dose-Response Relationship, Drug | 12 | 2019 | 1372 | 0.520 |
Why?
| Benzoquinones | 4 | 2025 | 32 | 0.520 |
Why?
| Young Adult | 17 | 2023 | 4113 | 0.510 |
Why?
| Infant | 21 | 2022 | 3630 | 0.500 |
Why?
| Cystic Fibrosis | 1 | 2018 | 147 | 0.490 |
Why?
| Reactive Nitrogen Species | 3 | 2015 | 23 | 0.480 |
Why?
| Keratin-18 | 2 | 2021 | 14 | 0.480 |
Why?
| Proliferating Cell Nuclear Antigen | 4 | 2019 | 68 | 0.480 |
Why?
| Bile Acids and Salts | 1 | 2015 | 78 | 0.480 |
Why?
| HMGB1 Protein | 2 | 2021 | 21 | 0.480 |
Why?
| Lung | 1 | 2019 | 504 | 0.480 |
Why?
| Mass Spectrometry | 4 | 2014 | 285 | 0.470 |
Why?
| Tyrosine | 4 | 2007 | 94 | 0.470 |
Why?
| Mice, Inbred Strains | 7 | 2019 | 160 | 0.460 |
Why?
| Isoniazid | 1 | 2014 | 33 | 0.450 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 121 | 0.450 |
Why?
| Adult | 24 | 2025 | 13604 | 0.440 |
Why?
| Carnitine | 1 | 2014 | 63 | 0.430 |
Why?
| Disease Models, Animal | 7 | 2020 | 1436 | 0.430 |
Why?
| Autoantibodies | 1 | 2014 | 117 | 0.430 |
Why?
| Trifluoperazine | 1 | 2012 | 6 | 0.410 |
Why?
| Sensitivity and Specificity | 9 | 2016 | 862 | 0.400 |
Why?
| Viperidae | 1 | 2012 | 5 | 0.400 |
Why?
| Crotalid Venoms | 1 | 2012 | 8 | 0.400 |
Why?
| Antivenins | 1 | 2012 | 9 | 0.400 |
Why?
| Anti-Ulcer Agents | 3 | 2007 | 21 | 0.400 |
Why?
| Immunoglobulin Fragments | 1 | 2012 | 14 | 0.400 |
Why?
| Tomography, X-Ray Computed | 1 | 2018 | 1164 | 0.400 |
Why?
| Snake Bites | 1 | 2012 | 14 | 0.400 |
Why?
| Echinomycin | 1 | 2011 | 6 | 0.390 |
Why?
| Hepatitis, Viral, Human | 2 | 2024 | 7 | 0.390 |
Why?
| Prospective Studies | 12 | 2024 | 2383 | 0.370 |
Why?
| Hospitalization | 4 | 2017 | 676 | 0.370 |
Why?
| Half-Life | 6 | 2019 | 86 | 0.370 |
Why?
| Hypersensitivity | 1 | 2012 | 75 | 0.370 |
Why?
| Cannabinoids | 5 | 2013 | 105 | 0.370 |
Why?
| Spider Venoms | 1 | 2011 | 6 | 0.370 |
Why?
| Middle Aged | 18 | 2024 | 12615 | 0.370 |
Why?
| Enzyme Inhibitors | 5 | 2019 | 377 | 0.370 |
Why?
| Necrosis | 6 | 2019 | 174 | 0.370 |
Why?
| Phosphoric Diester Hydrolases | 1 | 2011 | 33 | 0.360 |
Why?
| Indocyanine Green | 1 | 2010 | 34 | 0.350 |
Why?
| Arkansas | 8 | 2025 | 1991 | 0.350 |
Why?
| Students | 2 | 2023 | 223 | 0.350 |
Why?
| Macrolides | 3 | 2022 | 16 | 0.330 |
Why?
| Models, Biological | 7 | 2024 | 716 | 0.330 |
Why?
| Methamphetamine | 3 | 2013 | 194 | 0.330 |
Why?
| Central Nervous System Stimulants | 3 | 2013 | 209 | 0.320 |
Why?
| Triazoles | 3 | 2022 | 113 | 0.320 |
Why?
| Metabolomics | 3 | 2015 | 135 | 0.310 |
Why?
| Protein Binding | 5 | 2017 | 654 | 0.310 |
Why?
| Homeostasis | 3 | 2020 | 204 | 0.300 |
Why?
| Chemokines | 2 | 2010 | 75 | 0.290 |
Why?
| Research Subjects | 2 | 2019 | 51 | 0.290 |
Why?
| Community-Based Participatory Research | 2 | 2021 | 198 | 0.290 |
Why?
| Chemokine CCL2 | 2 | 2005 | 68 | 0.290 |
Why?
| Glutathione | 5 | 2025 | 299 | 0.280 |
Why?
| Poisoning | 2 | 2006 | 19 | 0.280 |
Why?
| Interleukin-6 | 3 | 2012 | 262 | 0.280 |
Why?
| Area Under Curve | 8 | 2019 | 179 | 0.280 |
Why?
| Tandem Mass Spectrometry | 6 | 2018 | 238 | 0.270 |
Why?
| Interleukin-8 | 3 | 2012 | 85 | 0.270 |
Why?
| Pandemics | 2 | 2022 | 568 | 0.270 |
Why?
| Caustics | 1 | 2006 | 5 | 0.270 |
Why?
| Signal Transduction | 5 | 2019 | 1624 | 0.270 |
Why?
| Burns, Chemical | 1 | 2006 | 9 | 0.270 |
Why?
| Cell Death | 4 | 2020 | 175 | 0.260 |
Why?
| Hypoxia-Inducible Factor 1 | 1 | 2006 | 3 | 0.260 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 22 | 0.260 |
Why?
| Cross-Sectional Studies | 3 | 2022 | 1611 | 0.260 |
Why?
| Infant, Premature | 4 | 2016 | 317 | 0.250 |
Why?
| Antidotes | 4 | 2011 | 27 | 0.250 |
Why?
| Gene Expression Regulation | 3 | 2016 | 955 | 0.250 |
Why?
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 39 | 0.250 |
Why?
| Liver Function Tests | 2 | 2002 | 45 | 0.250 |
Why?
| Reactive Oxygen Species | 3 | 2015 | 409 | 0.240 |
Why?
| Predictive Value of Tests | 5 | 2016 | 932 | 0.240 |
Why?
| Peroxynitrous Acid | 2 | 2007 | 33 | 0.240 |
Why?
| Infant, Newborn | 10 | 2018 | 2768 | 0.240 |
Why?
| Cytochrome P-450 Enzyme System | 3 | 2015 | 194 | 0.230 |
Why?
| Universities | 2 | 2023 | 170 | 0.230 |
Why?
| Up-Regulation | 4 | 2018 | 446 | 0.230 |
Why?
| Ion Channels | 1 | 2004 | 74 | 0.230 |
Why?
| Immunohistochemistry | 3 | 2012 | 957 | 0.230 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2024 | 49 | 0.220 |
Why?
| Blood Pressure Monitoring, Ambulatory | 2 | 2015 | 37 | 0.220 |
Why?
| Gastric Acidity Determination | 1 | 2003 | 12 | 0.220 |
Why?
| Biotransformation | 4 | 2015 | 84 | 0.220 |
Why?
| Aminoglycosides | 1 | 2023 | 18 | 0.220 |
Why?
| Chromatography, Liquid | 6 | 2018 | 231 | 0.220 |
Why?
| Glucuronosyltransferase | 3 | 2017 | 122 | 0.220 |
Why?
| Diagnosis, Differential | 4 | 2024 | 1033 | 0.210 |
Why?
| Medication Adherence | 1 | 2024 | 129 | 0.210 |
Why?
| Administration, Oral | 7 | 2018 | 434 | 0.210 |
Why?
| Pilot Projects | 4 | 2021 | 702 | 0.200 |
Why?
| Granzymes | 2 | 2020 | 10 | 0.200 |
Why?
| Membrane Glycoproteins | 1 | 2003 | 245 | 0.200 |
Why?
| Designer Drugs | 2 | 2013 | 22 | 0.200 |
Why?
| Aged | 7 | 2024 | 9747 | 0.200 |
Why?
| Vitamins | 1 | 2022 | 63 | 0.200 |
Why?
| Digestive System | 1 | 2002 | 15 | 0.200 |
Why?
| Community-Acquired Infections | 1 | 2022 | 39 | 0.200 |
Why?
| Pneumonia, Bacterial | 1 | 2022 | 28 | 0.200 |
Why?
| Obesity | 2 | 2022 | 1121 | 0.200 |
Why?
| Vitamin D | 1 | 2022 | 87 | 0.190 |
Why?
| Gastrointestinal Agents | 1 | 2002 | 35 | 0.190 |
Why?
| Retrospective Studies | 9 | 2024 | 6272 | 0.190 |
Why?
| Phosphatidic Acids | 2 | 2019 | 6 | 0.190 |
Why?
| Parents | 1 | 2025 | 318 | 0.190 |
Why?
| Anti-Infective Agents | 2 | 2013 | 95 | 0.190 |
Why?
| United States | 7 | 2022 | 4964 | 0.190 |
Why?
| Photography | 1 | 2021 | 30 | 0.190 |
Why?
| Microsomes, Liver | 4 | 2015 | 183 | 0.190 |
Why?
| Sexual Behavior | 1 | 2022 | 118 | 0.180 |
Why?
| Metabolic Clearance Rate | 5 | 2018 | 69 | 0.180 |
Why?
| Dried Blood Spot Testing | 2 | 2018 | 5 | 0.180 |
Why?
| Oxidation-Reduction | 6 | 2023 | 316 | 0.180 |
Why?
| Gastrointestinal Diseases | 1 | 2002 | 125 | 0.180 |
Why?
| Healthcare Disparities | 1 | 2024 | 281 | 0.180 |
Why?
| Bayes Theorem | 3 | 2012 | 107 | 0.180 |
Why?
| Aged, 80 and over | 4 | 2021 | 3227 | 0.170 |
Why?
| Hydroxyurea | 1 | 2020 | 29 | 0.170 |
Why?
| Substance-Related Disorders | 3 | 2022 | 611 | 0.170 |
Why?
| Polymorphism, Genetic | 2 | 2018 | 180 | 0.170 |
Why?
| Cell Line | 3 | 2017 | 988 | 0.170 |
Why?
| Heart Arrest | 1 | 2022 | 155 | 0.170 |
Why?
| Histamine H2 Antagonists | 3 | 2005 | 26 | 0.170 |
Why?
| Recombinant Proteins | 4 | 2018 | 476 | 0.160 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 192 | 0.160 |
Why?
| Brain | 3 | 2025 | 1339 | 0.160 |
Why?
| Lipids | 1 | 2020 | 152 | 0.160 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 9 | 0.160 |
Why?
| Binding Sites | 2 | 2017 | 362 | 0.160 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2022 | 574 | 0.160 |
Why?
| Prothrombin Time | 3 | 2005 | 18 | 0.160 |
Why?
| Mice, Knockout | 4 | 2011 | 844 | 0.160 |
Why?
| Stress, Physiological | 1 | 2020 | 172 | 0.160 |
Why?
| Glycerol-3-Phosphate O-Acyltransferase | 1 | 2019 | 4 | 0.160 |
Why?
| ortho-Aminobenzoates | 1 | 2019 | 6 | 0.160 |
Why?
| Carbachol | 1 | 2019 | 27 | 0.160 |
Why?
| Time Factors | 5 | 2013 | 2939 | 0.160 |
Why?
| Respiratory Hypersensitivity | 1 | 2019 | 17 | 0.160 |
Why?
| Child, Hospitalized | 1 | 2019 | 30 | 0.160 |
Why?
| Organ Culture Techniques | 1 | 2019 | 47 | 0.160 |
Why?
| Liver Cirrhosis | 1 | 2021 | 229 | 0.160 |
Why?
| Drug Administration Schedule | 4 | 2021 | 370 | 0.160 |
Why?
| Disclosure | 1 | 2019 | 39 | 0.160 |
Why?
| Case-Control Studies | 3 | 2018 | 1158 | 0.160 |
Why?
| Bacterial Infections | 2 | 2017 | 95 | 0.150 |
Why?
| Body Weight | 3 | 2018 | 518 | 0.150 |
Why?
| Seroepidemiologic Studies | 3 | 2023 | 48 | 0.150 |
Why?
| Cannabidiol | 1 | 2019 | 40 | 0.150 |
Why?
| Research Personnel | 1 | 2019 | 65 | 0.150 |
Why?
| Protein Biosynthesis | 2 | 2017 | 232 | 0.150 |
Why?
| Oropharynx | 2 | 2009 | 13 | 0.150 |
Why?
| Health Status Disparities | 1 | 2021 | 202 | 0.150 |
Why?
| Ampicillin | 1 | 2018 | 6 | 0.150 |
Why?
| Hepatitis, Autoimmune | 1 | 2018 | 27 | 0.150 |
Why?
| HSP72 Heat-Shock Proteins | 1 | 2018 | 8 | 0.150 |
Why?
| Phosphatidate Phosphatase | 1 | 2018 | 14 | 0.150 |
Why?
| Information Dissemination | 1 | 2019 | 80 | 0.150 |
Why?
| Albuterol | 1 | 2019 | 57 | 0.150 |
Why?
| Treatment Outcome | 6 | 2019 | 5284 | 0.150 |
Why?
| Education, Nonprofessional | 1 | 2017 | 8 | 0.150 |
Why?
| Human Experimentation | 1 | 2017 | 11 | 0.150 |
Why?
| Mass Screening | 1 | 2021 | 344 | 0.150 |
Why?
| Sirtuin 1 | 1 | 2017 | 28 | 0.150 |
Why?
| Sulfonamides | 1 | 2019 | 126 | 0.150 |
Why?
| Teicoplanin | 1 | 2017 | 4 | 0.140 |
Why?
| Teaching Materials | 1 | 2017 | 32 | 0.140 |
Why?
| 3' Untranslated Regions | 1 | 2017 | 52 | 0.140 |
Why?
| Patient Participation | 1 | 2018 | 70 | 0.140 |
Why?
| Health Services Research | 1 | 2018 | 152 | 0.140 |
Why?
| Rural Population | 2 | 2021 | 555 | 0.140 |
Why?
| Severity of Illness Index | 3 | 2024 | 978 | 0.140 |
Why?
| Absorptiometry, Photon | 1 | 2018 | 156 | 0.140 |
Why?
| Substance Abuse Detection | 2 | 2022 | 90 | 0.140 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 510 | 0.140 |
Why?
| Reading | 1 | 2017 | 85 | 0.140 |
Why?
| Electrochemical Techniques | 1 | 2016 | 11 | 0.140 |
Why?
| Anthropometry | 2 | 2015 | 95 | 0.130 |
Why?
| Nuclear Proteins | 1 | 2018 | 238 | 0.130 |
Why?
| Comprehension | 1 | 2017 | 116 | 0.130 |
Why?
| Age Factors | 3 | 2015 | 1111 | 0.130 |
Why?
| Saliva | 1 | 2016 | 55 | 0.130 |
Why?
| Vitamin A | 1 | 2016 | 14 | 0.130 |
Why?
| Liver Failure | 1 | 2016 | 21 | 0.130 |
Why?
| Amphetamine | 2 | 2013 | 38 | 0.130 |
Why?
| Nitric Oxide Synthase Type I | 2 | 2015 | 10 | 0.130 |
Why?
| Point-of-Care Systems | 1 | 2016 | 57 | 0.130 |
Why?
| Injections, Intravenous | 3 | 2012 | 137 | 0.130 |
Why?
| Caffeine | 1 | 2016 | 64 | 0.130 |
Why?
| Blood Proteins | 2 | 2006 | 84 | 0.130 |
Why?
| Blood Pressure Monitors | 1 | 2015 | 10 | 0.130 |
Why?
| Biomedical Research | 1 | 2019 | 246 | 0.130 |
Why?
| Taurodeoxycholic Acid | 1 | 2015 | 6 | 0.130 |
Why?
| Glycodeoxycholic Acid | 1 | 2015 | 6 | 0.130 |
Why?
| Glycochenodeoxycholic Acid | 1 | 2015 | 6 | 0.130 |
Why?
| Guanidines | 1 | 2015 | 29 | 0.130 |
Why?
| Keratin-8 | 1 | 2015 | 3 | 0.130 |
Why?
| Styrene | 1 | 2015 | 9 | 0.120 |
Why?
| Bone Density | 1 | 2018 | 387 | 0.120 |
Why?
| Delayed-Action Preparations | 2 | 2012 | 56 | 0.120 |
Why?
| Prodrugs | 2 | 2012 | 31 | 0.120 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 71 | 0.120 |
Why?
| Solid Phase Extraction | 2 | 2013 | 12 | 0.120 |
Why?
| Tablets | 3 | 2013 | 31 | 0.120 |
Why?
| Breast Neoplasms | 1 | 2024 | 1200 | 0.120 |
Why?
| Cross-Over Studies | 2 | 2012 | 228 | 0.120 |
Why?
| Immunity, Innate | 1 | 2016 | 105 | 0.120 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2014 | 2 | 0.120 |
Why?
| Nitrates | 2 | 2011 | 30 | 0.120 |
Why?
| Administration, Intravenous | 3 | 2019 | 70 | 0.120 |
Why?
| Cells, Cultured | 4 | 2017 | 1571 | 0.120 |
Why?
| Famotidine | 2 | 2005 | 11 | 0.110 |
Why?
| Discriminant Analysis | 1 | 2014 | 26 | 0.110 |
Why?
| Environmental Pollutants | 1 | 2015 | 102 | 0.110 |
Why?
| Least-Squares Analysis | 1 | 2014 | 40 | 0.110 |
Why?
| Urinalysis | 1 | 2014 | 33 | 0.110 |
Why?
| Superoxide Dismutase | 2 | 2011 | 116 | 0.110 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2012 | 393 | 0.110 |
Why?
| Wounds, Stab | 1 | 2013 | 6 | 0.110 |
Why?
| Cannabis | 2 | 2019 | 146 | 0.110 |
Why?
| Fentanyl | 1 | 2014 | 36 | 0.110 |
Why?
| Cyclosporine | 2 | 2011 | 66 | 0.110 |
Why?
| Basal Ganglia | 1 | 2013 | 27 | 0.110 |
Why?
| Neck Injuries | 1 | 2013 | 21 | 0.110 |
Why?
| Benzoflavones | 1 | 2013 | 3 | 0.110 |
Why?
| Sulfaphenazole | 1 | 2013 | 4 | 0.110 |
Why?
| Nonlinear Dynamics | 2 | 2012 | 18 | 0.110 |
Why?
| Self-Injurious Behavior | 1 | 2013 | 28 | 0.110 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2012 | 474 | 0.110 |
Why?
| Cohort Studies | 3 | 2019 | 1456 | 0.110 |
Why?
| Kinetics | 4 | 2018 | 623 | 0.100 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2012 | 16 | 0.100 |
Why?
| Mycophenolic Acid | 1 | 2012 | 18 | 0.100 |
Why?
| Myoglobin | 1 | 2013 | 25 | 0.100 |
Why?
| Receptors, Phospholipase A2 | 1 | 2012 | 14 | 0.100 |
Why?
| Neurotoxicity Syndromes | 1 | 2013 | 46 | 0.100 |
Why?
| Indicators and Reagents | 1 | 2012 | 37 | 0.100 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 24 | 0.100 |
Why?
| Dinoprostone | 1 | 2012 | 47 | 0.100 |
Why?
| Permeability | 1 | 2012 | 67 | 0.100 |
Why?
| Antibodies, Viral | 2 | 2023 | 93 | 0.100 |
Why?
| Flushing | 1 | 2012 | 4 | 0.100 |
Why?
| Piperacillin | 1 | 2012 | 23 | 0.100 |
Why?
| Fasting | 1 | 2012 | 73 | 0.100 |
Why?
| Immunoglobulin Fab Fragments | 1 | 2012 | 15 | 0.100 |
Why?
| Blood Specimen Collection | 1 | 2012 | 35 | 0.100 |
Why?
| T-Lymphocytes | 1 | 2014 | 325 | 0.100 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 102 | 0.100 |
Why?
| Insulin | 1 | 2014 | 467 | 0.100 |
Why?
| Erythema | 1 | 2012 | 36 | 0.100 |
Why?
| Metronidazole | 1 | 2012 | 28 | 0.100 |
Why?
| Exanthema | 1 | 2012 | 31 | 0.100 |
Why?
| Lipopolysaccharides | 1 | 2013 | 197 | 0.100 |
Why?
| Pruritus | 1 | 2012 | 43 | 0.100 |
Why?
| Cardiopulmonary Bypass | 1 | 2012 | 93 | 0.100 |
Why?
| Ketamine | 1 | 2012 | 59 | 0.100 |
Why?
| Heart Septal Defects, Ventricular | 1 | 2012 | 45 | 0.100 |
Why?
| Vancomycin | 1 | 2012 | 79 | 0.100 |
Why?
| Neutropenia | 1 | 2012 | 116 | 0.090 |
Why?
| Sex Factors | 1 | 2014 | 711 | 0.090 |
Why?
| Cellulitis | 1 | 2011 | 10 | 0.090 |
Why?
| Receptor, Cannabinoid, CB1 | 1 | 2012 | 123 | 0.090 |
Why?
| Neuroprotective Agents | 1 | 2012 | 100 | 0.090 |
Why?
| Nitroimidazoles | 1 | 2011 | 16 | 0.090 |
Why?
| Anemia, Hemolytic | 1 | 2011 | 10 | 0.090 |
Why?
| Rhabdomyolysis | 1 | 2011 | 12 | 0.090 |
Why?
| Hair | 1 | 2011 | 25 | 0.090 |
Why?
| Hypertension | 2 | 2015 | 546 | 0.090 |
Why?
| Anti-Inflammatory Agents | 1 | 2012 | 163 | 0.090 |
Why?
| Coloring Agents | 1 | 2010 | 66 | 0.090 |
Why?
| Brain Injuries | 1 | 2012 | 159 | 0.090 |
Why?
| Kidney Transplantation | 1 | 2012 | 189 | 0.090 |
Why?
| Muscular Diseases | 1 | 2011 | 61 | 0.090 |
Why?
| Interleukin-10 | 2 | 2012 | 84 | 0.090 |
Why?
| Immunoblotting | 1 | 2010 | 115 | 0.080 |
Why?
| Liver Circulation | 1 | 2010 | 22 | 0.080 |
Why?
| Play and Playthings | 1 | 2009 | 12 | 0.080 |
Why?
| Sodium Oxybate | 1 | 2009 | 11 | 0.080 |
Why?
| Butylene Glycols | 1 | 2009 | 14 | 0.080 |
Why?
| Coma | 1 | 2009 | 16 | 0.080 |
Why?
| Kidney Diseases | 1 | 2012 | 213 | 0.080 |
Why?
| Linear Models | 2 | 2012 | 279 | 0.080 |
Why?
| Blood Pressure | 1 | 2012 | 532 | 0.080 |
Why?
| Databases as Topic | 1 | 2009 | 37 | 0.080 |
Why?
| Immunosuppressive Agents | 1 | 2011 | 225 | 0.080 |
Why?
| Environmental Exposure | 1 | 2011 | 199 | 0.080 |
Why?
| Foreign Bodies | 1 | 2009 | 63 | 0.080 |
Why?
| Drug Compounding | 1 | 2008 | 25 | 0.080 |
Why?
| Blood Chemical Analysis | 1 | 2008 | 28 | 0.080 |
Why?
| Incidence | 1 | 2012 | 1032 | 0.080 |
Why?
| Cesium | 1 | 2008 | 8 | 0.080 |
Why?
| Registries | 2 | 2024 | 563 | 0.080 |
Why?
| Chlorides | 1 | 2008 | 49 | 0.080 |
Why?
| Probability | 1 | 2008 | 164 | 0.080 |
Why?
| DNA | 1 | 2011 | 535 | 0.080 |
Why?
| Macrophages | 2 | 2017 | 364 | 0.070 |
Why?
| Analgesics, Opioid | 1 | 2014 | 576 | 0.070 |
Why?
| Chloroform | 1 | 2007 | 5 | 0.070 |
Why?
| Models, Statistical | 1 | 2009 | 226 | 0.070 |
Why?
| Free Radical Scavengers | 2 | 2011 | 25 | 0.070 |
Why?
| Magnetic Resonance Imaging | 2 | 2012 | 1548 | 0.070 |
Why?
| Infusions, Intravenous | 2 | 2023 | 213 | 0.070 |
Why?
| Acute Kidney Injury | 1 | 2011 | 303 | 0.070 |
Why?
| Sulfuric Acids | 1 | 2006 | 8 | 0.070 |
Why?
| Electrocardiography | 1 | 2008 | 264 | 0.070 |
Why?
| Genotype | 3 | 2018 | 532 | 0.070 |
Why?
| Aerobiosis | 1 | 2006 | 14 | 0.070 |
Why?
| Analysis of Variance | 1 | 2007 | 553 | 0.070 |
Why?
| Emergency Medicine | 1 | 2006 | 52 | 0.060 |
Why?
| Hepatitis C, Chronic | 2 | 2018 | 85 | 0.060 |
Why?
| Toxicity Tests | 1 | 2006 | 54 | 0.060 |
Why?
| Antioxidants | 2 | 2023 | 239 | 0.060 |
Why?
| Reproducibility of Results | 3 | 2015 | 1203 | 0.060 |
Why?
| Phosphorylation | 2 | 2019 | 525 | 0.060 |
Why?
| Cell Nucleus | 1 | 2006 | 182 | 0.060 |
Why?
| Mice, Transgenic | 2 | 2018 | 540 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 234 | 0.060 |
Why?
| Metabolic Detoxication, Phase II | 2 | 2017 | 11 | 0.060 |
Why?
| Mitochondrial Membrane Transport Proteins | 1 | 2004 | 18 | 0.060 |
Why?
| Child Abuse | 1 | 2006 | 136 | 0.060 |
Why?
| Receptors, Progesterone | 1 | 2024 | 64 | 0.060 |
Why?
| Computer Simulation | 2 | 2017 | 282 | 0.060 |
Why?
| Kupffer Cells | 1 | 2003 | 11 | 0.060 |
Why?
| Risk Assessment | 1 | 2008 | 1269 | 0.060 |
Why?
| Glutathione Disulfide | 1 | 2003 | 40 | 0.060 |
Why?
| Single-Blind Method | 2 | 2015 | 114 | 0.060 |
Why?
| Models, Chemical | 2 | 2015 | 64 | 0.060 |
Why?
| Superoxides | 1 | 2003 | 46 | 0.060 |
Why?
| Papillomavirus Vaccines | 1 | 2025 | 67 | 0.050 |
Why?
| Pyruvic Acid | 1 | 2023 | 21 | 0.050 |
Why?
| Receptors, Estrogen | 1 | 2024 | 132 | 0.050 |
Why?
| Alanine | 1 | 2023 | 43 | 0.050 |
Why?
| Omeprazole | 1 | 2003 | 17 | 0.050 |
Why?
| Ischemia | 1 | 2024 | 153 | 0.050 |
Why?
| Mixed Function Oxygenases | 1 | 2003 | 25 | 0.050 |
Why?
| Injections, Intraperitoneal | 1 | 2003 | 59 | 0.050 |
Why?
| Prognosis | 3 | 2015 | 1978 | 0.050 |
Why?
| Safety | 1 | 2003 | 77 | 0.050 |
Why?
| Hydrogen Peroxide | 1 | 2003 | 113 | 0.050 |
Why?
| Immunoenzyme Techniques | 1 | 2003 | 137 | 0.050 |
Why?
| Oxygen | 1 | 2006 | 322 | 0.050 |
Why?
| Radiographic Image Enhancement | 1 | 2003 | 31 | 0.050 |
Why?
| Genetic Variation | 1 | 2024 | 208 | 0.050 |
Why?
| Pediatrics | 1 | 2006 | 283 | 0.050 |
Why?
| Tibial Fractures | 1 | 2003 | 31 | 0.050 |
Why?
| Logistic Models | 2 | 2018 | 899 | 0.050 |
Why?
| Drug Interactions | 1 | 2003 | 206 | 0.050 |
Why?
| Molecular Structure | 2 | 2013 | 296 | 0.050 |
Why?
| Papillomavirus Infections | 1 | 2025 | 168 | 0.050 |
Why?
| Vaccination | 1 | 2025 | 280 | 0.050 |
Why?
| Liver Transplantation | 1 | 2024 | 154 | 0.050 |
Why?
| Membrane Potential, Mitochondrial | 2 | 2015 | 36 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2003 | 251 | 0.050 |
Why?
| Neoplasms | 1 | 2012 | 1252 | 0.050 |
Why?
| Hydroxylation | 2 | 2012 | 61 | 0.050 |
Why?
| Glutamate Dehydrogenase | 1 | 2021 | 16 | 0.050 |
Why?
| Death, Sudden, Cardiac | 1 | 2022 | 57 | 0.050 |
Why?
| Nitric Oxide | 1 | 2003 | 259 | 0.050 |
Why?
| Psychotropic Drugs | 1 | 2022 | 76 | 0.050 |
Why?
| Databases, Factual | 1 | 2024 | 673 | 0.050 |
Why?
| Uncertainty | 1 | 2021 | 44 | 0.050 |
Why?
| Kidney Failure, Chronic | 1 | 2003 | 201 | 0.040 |
Why?
| Longitudinal Studies | 1 | 2023 | 737 | 0.040 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 491 | 0.040 |
Why?
| Apoptosis | 1 | 2006 | 1097 | 0.040 |
Why?
| Gestational Age | 2 | 2012 | 394 | 0.040 |
Why?
| Anti-Asthmatic Agents | 1 | 2020 | 29 | 0.040 |
Why?
| Decision Making | 1 | 2002 | 272 | 0.040 |
Why?
| Australia | 1 | 2019 | 86 | 0.040 |
Why?
| Risk Factors | 3 | 2012 | 3724 | 0.040 |
Why?
| Research Design | 1 | 2021 | 353 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 151 | 0.040 |
Why?
| Tissue Distribution | 2 | 2013 | 166 | 0.040 |
Why?
| Hepatitis Viruses | 1 | 2018 | 2 | 0.040 |
Why?
| Qualitative Research | 1 | 2021 | 350 | 0.040 |
Why?
| beta Catenin | 1 | 2019 | 97 | 0.040 |
Why?
| Metagenomics | 1 | 2018 | 42 | 0.040 |
Why?
| Mallory Bodies | 1 | 2018 | 1 | 0.040 |
Why?
| Drug Dosage Calculations | 1 | 2018 | 11 | 0.040 |
Why?
| Acute-Phase Reaction | 1 | 2018 | 8 | 0.040 |
Why?
| RNA, Viral | 1 | 2018 | 107 | 0.040 |
Why?
| Pregnancy | 1 | 2025 | 2504 | 0.040 |
Why?
| DNA, Viral | 1 | 2018 | 136 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2018 | 78 | 0.040 |
Why?
| Ethics, Research | 1 | 2017 | 39 | 0.040 |
Why?
| Metabolic Networks and Pathways | 1 | 2018 | 92 | 0.040 |
Why?
| Metabolic Detoxication, Phase I | 1 | 2017 | 11 | 0.040 |
Why?
| Gas Chromatography-Mass Spectrometry | 2 | 2011 | 68 | 0.040 |
Why?
| MAP Kinase Signaling System | 1 | 2018 | 117 | 0.040 |
Why?
| Gene Frequency | 1 | 2017 | 96 | 0.040 |
Why?
| Glucuronides | 1 | 2017 | 45 | 0.040 |
Why?
| Plant Extracts | 1 | 2019 | 174 | 0.030 |
Why?
| Rats | 2 | 2014 | 3292 | 0.030 |
Why?
| Communication | 1 | 2019 | 250 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 169 | 0.030 |
Why?
| Residence Characteristics | 1 | 2017 | 150 | 0.030 |
Why?
| Liver Diseases, Alcoholic | 1 | 2016 | 33 | 0.030 |
Why?
| Oscillometry | 1 | 2015 | 9 | 0.030 |
Why?
| Health Literacy | 1 | 2017 | 129 | 0.030 |
Why?
| NAD | 1 | 2015 | 41 | 0.030 |
Why?
| Sex Characteristics | 1 | 2017 | 198 | 0.030 |
Why?
| Diastole | 1 | 2015 | 70 | 0.030 |
Why?
| Arm | 1 | 2015 | 47 | 0.030 |
Why?
| Systole | 1 | 2015 | 72 | 0.030 |
Why?
| Binding, Competitive | 1 | 2015 | 94 | 0.030 |
Why?
| Observer Variation | 1 | 2015 | 139 | 0.030 |
Why?
| Patient Safety | 1 | 2016 | 102 | 0.030 |
Why?
| Substrate Specificity | 1 | 2015 | 192 | 0.030 |
Why?
| Clinical Protocols | 1 | 2015 | 110 | 0.030 |
Why?
| Suramin | 1 | 2014 | 13 | 0.030 |
Why?
| Cell Proliferation | 1 | 2019 | 985 | 0.030 |
Why?
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 3 | 0.030 |
Why?
| Fas Ligand Protein | 1 | 2014 | 17 | 0.030 |
Why?
| Antigens, Ly | 1 | 2014 | 9 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 181 | 0.030 |
Why?
| Islets of Langerhans | 1 | 2014 | 25 | 0.030 |
Why?
| Oxygen Consumption | 1 | 2015 | 190 | 0.030 |
Why?
| Glucose Tolerance Test | 1 | 2014 | 58 | 0.030 |
Why?
| Algorithms | 1 | 2018 | 631 | 0.030 |
Why?
| Gene Silencing | 1 | 2014 | 115 | 0.030 |
Why?
| Thiazolidinediones | 1 | 2014 | 82 | 0.030 |
Why?
| Biological Availability | 2 | 2005 | 102 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 7 | 0.030 |
Why?
| Paper | 1 | 2013 | 15 | 0.030 |
Why?
| Capsules | 1 | 2013 | 28 | 0.030 |
Why?
| Powders | 1 | 2013 | 22 | 0.030 |
Why?
| Glutathione Transferase | 1 | 2014 | 172 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 17 | 0.030 |
Why?
| Ethanol | 1 | 2016 | 336 | 0.030 |
Why?
| Body Temperature Regulation | 1 | 2013 | 22 | 0.030 |
Why?
| Benzodioxoles | 1 | 2013 | 40 | 0.030 |
Why?
| Pyrrolidines | 1 | 2013 | 67 | 0.030 |
Why?
| Hallucinogens | 1 | 2013 | 65 | 0.030 |
Why?
| Fatal Outcome | 1 | 2013 | 197 | 0.030 |
Why?
| Heterozygote | 1 | 2012 | 83 | 0.030 |
Why?
| Drug Resistance | 1 | 2012 | 65 | 0.030 |
Why?
| Pyrans | 1 | 2012 | 16 | 0.030 |
Why?
| Cell Survival | 1 | 2014 | 589 | 0.030 |
Why?
| Prescription Drugs | 1 | 2012 | 37 | 0.030 |
Why?
| Amine Oxidase (Copper-Containing) | 1 | 2012 | 3 | 0.030 |
Why?
| Placebo Effect | 1 | 2012 | 17 | 0.030 |
Why?
| Interleukin-3 | 1 | 2012 | 13 | 0.030 |
Why?
| Fever | 1 | 2013 | 112 | 0.030 |
Why?
| Calcitonin Gene-Related Peptide | 1 | 2012 | 23 | 0.020 |
Why?
| Intention to Treat Analysis | 1 | 2012 | 28 | 0.020 |
Why?
| Histamine | 1 | 2012 | 25 | 0.020 |
Why?
| Disease Progression | 1 | 2015 | 829 | 0.020 |
Why?
| Protein Precursors | 1 | 2012 | 43 | 0.020 |
Why?
| Calcitonin | 1 | 2012 | 30 | 0.020 |
Why?
| Glucose | 1 | 2014 | 341 | 0.020 |
Why?
| Insurance, Health, Reimbursement | 1 | 2012 | 24 | 0.020 |
Why?
| Dopamine | 1 | 2013 | 175 | 0.020 |
Why?
| Spectroscopy, Near-Infrared | 1 | 2012 | 52 | 0.020 |
Why?
| Population | 1 | 2012 | 9 | 0.020 |
Why?
| Office Visits | 1 | 2012 | 44 | 0.020 |
Why?
| Genetic Association Studies | 1 | 2012 | 119 | 0.020 |
Why?
| Ligands | 1 | 2012 | 203 | 0.020 |
Why?
| Hyperthermia, Induced | 1 | 2013 | 115 | 0.020 |
Why?
| Expectorants | 1 | 2011 | 14 | 0.020 |
Why?
| Risk | 1 | 2012 | 324 | 0.020 |
Why?
| Glucuronic Acid | 1 | 2011 | 8 | 0.020 |
Why?
| Creatinine | 1 | 2012 | 145 | 0.020 |
Why?
| Central Nervous System | 1 | 2012 | 83 | 0.020 |
Why?
| Microsomes | 1 | 2011 | 35 | 0.020 |
Why?
| Monte Carlo Method | 1 | 2012 | 85 | 0.020 |
Why?
| ROC Curve | 1 | 2012 | 228 | 0.020 |
Why?
| Deuterium | 1 | 2011 | 45 | 0.020 |
Why?
| Reference Standards | 1 | 2011 | 52 | 0.020 |
Why?
| Statistics as Topic | 1 | 2011 | 89 | 0.020 |
Why?
| Birth Weight | 1 | 2012 | 106 | 0.020 |
Why?
| Syndrome | 1 | 2012 | 240 | 0.020 |
Why?
| Cytoplasm | 1 | 2011 | 89 | 0.020 |
Why?
| Forensic Toxicology | 1 | 2011 | 4 | 0.020 |
Why?
| Muscular Dystrophies | 1 | 2011 | 15 | 0.020 |
Why?
| Hair Color | 1 | 2011 | 10 | 0.020 |
Why?
| Spinal Muscular Atrophies of Childhood | 1 | 2011 | 9 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2012 | 144 | 0.020 |
Why?
| Glucuronidase | 1 | 2011 | 48 | 0.020 |
Why?
| Protein Isoforms | 1 | 2011 | 116 | 0.020 |
Why?
| Crime | 1 | 2011 | 25 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2012 | 583 | 0.020 |
Why?
| Transaminases | 1 | 2011 | 11 | 0.020 |
Why?
| Forecasting | 1 | 2012 | 147 | 0.020 |
Why?
| Staining and Labeling | 1 | 2011 | 96 | 0.020 |
Why?
| Bilirubin | 1 | 2011 | 40 | 0.020 |
Why?
| Intensive Care Units | 1 | 2012 | 225 | 0.020 |
Why?
| Blotting, Western | 1 | 2011 | 578 | 0.020 |
Why?
| Double-Blind Method | 1 | 2012 | 708 | 0.020 |
Why?
| Intestines | 1 | 2011 | 172 | 0.020 |
Why?
| Child Development | 1 | 2012 | 194 | 0.020 |
Why?
| Intestinal Mucosa | 1 | 2011 | 216 | 0.020 |
Why?
| Intensive Care Units, Pediatric | 1 | 2011 | 174 | 0.020 |
Why?
| Body Mass Index | 1 | 2013 | 678 | 0.020 |
Why?
| Suction | 1 | 2009 | 23 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2013 | 1585 | 0.020 |
Why?
| Alcohol Drinking | 1 | 2011 | 227 | 0.020 |
Why?
| Eating | 1 | 2009 | 158 | 0.020 |
Why?
| Kidney | 1 | 2013 | 696 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2011 | 486 | 0.020 |
Why?
| Survival Rate | 1 | 2011 | 909 | 0.020 |
Why?
| Alcoholism | 1 | 2011 | 235 | 0.020 |
Why?
| Nitric Oxide Synthase | 1 | 2007 | 74 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2013 | 786 | 0.020 |
Why?
| Carcinoma, Hepatocellular | 1 | 2008 | 195 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2008 | 326 | 0.010 |
Why?
| Follow-Up Studies | 1 | 2009 | 2243 | 0.010 |
Why?
| Electrophoresis, Gel, Pulsed-Field | 1 | 2003 | 29 | 0.010 |
Why?
| Specialization | 1 | 2003 | 46 | 0.010 |
Why?
| Medicine | 1 | 2003 | 56 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2003 | 449 | 0.010 |
Why?
| Endopeptidases | 1 | 2002 | 65 | 0.010 |
Why?
|
|
James's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|